[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IL126590A - Trihydrate salt of -5 (-2 (-4 (1 (2, 2-benzothiazole - 3yl) -1-piperazinyl) ethyl) - 6-chloro-1, 3-dihydro-2 (1H) - indole - 2On (= Ziprasidone) and pharmaceutical preparations containing it - Google Patents

Trihydrate salt of -5 (-2 (-4 (1 (2, 2-benzothiazole - 3yl) -1-piperazinyl) ethyl) - 6-chloro-1, 3-dihydro-2 (1H) - indole - 2On (= Ziprasidone) and pharmaceutical preparations containing it

Info

Publication number
IL126590A
IL126590A IL12659097A IL12659097A IL126590A IL 126590 A IL126590 A IL 126590A IL 12659097 A IL12659097 A IL 12659097A IL 12659097 A IL12659097 A IL 12659097A IL 126590 A IL126590 A IL 126590A
Authority
IL
Israel
Prior art keywords
ziprasidone
indol
mesylate
dihydro
chloro
Prior art date
Application number
IL12659097A
Other languages
English (en)
Hebrew (he)
Other versions
IL126590A0 (en
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IL126590A0 publication Critical patent/IL126590A0/xx
Publication of IL126590A publication Critical patent/IL126590A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL12659097A 1996-05-07 1997-03-26 Trihydrate salt of -5 (-2 (-4 (1 (2, 2-benzothiazole - 3yl) -1-piperazinyl) ethyl) - 6-chloro-1, 3-dihydro-2 (1H) - indole - 2On (= Ziprasidone) and pharmaceutical preparations containing it IL126590A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1653796P 1996-05-07 1996-05-07
PCT/IB1997/000306 WO1997042190A1 (en) 1996-05-07 1997-03-26 Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one (=ziprasidone), its preparation and its use as dopamine d2 antagonist

Publications (2)

Publication Number Publication Date
IL126590A0 IL126590A0 (en) 1999-08-17
IL126590A true IL126590A (en) 2001-11-25

Family

ID=21777622

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12659097A IL126590A (en) 1996-05-07 1997-03-26 Trihydrate salt of -5 (-2 (-4 (1 (2, 2-benzothiazole - 3yl) -1-piperazinyl) ethyl) - 6-chloro-1, 3-dihydro-2 (1H) - indole - 2On (= Ziprasidone) and pharmaceutical preparations containing it

Country Status (46)

Country Link
US (1) US6110918A (es)
EP (1) EP0904273B1 (es)
JP (1) JP3102896B2 (es)
KR (1) KR100333214B1 (es)
CN (1) CN1092658C (es)
AP (1) AP838A (es)
AR (1) AR007003A1 (es)
AT (1) ATE236902T1 (es)
AU (1) AU730856C (es)
BG (1) BG63601B1 (es)
BR (1) BR9708932A (es)
CA (1) CA2252895C (es)
CO (1) CO4940465A1 (es)
CZ (1) CZ289216B6 (es)
DE (1) DE69720719T2 (es)
DK (1) DK0904273T3 (es)
DZ (1) DZ2221A1 (es)
EA (1) EA001180B1 (es)
EG (1) EG24401A (es)
ES (1) ES2192264T3 (es)
GT (1) GT199700042A (es)
HK (1) HK1017893A1 (es)
HN (1) HN1997000040A (es)
HR (1) HRP970235B1 (es)
HU (1) HU229057B1 (es)
ID (1) ID17504A (es)
IL (1) IL126590A (es)
IS (1) IS2301B (es)
MA (1) MA26427A1 (es)
ME (1) ME00901B (es)
MY (1) MY128051A (es)
NO (1) NO312513B1 (es)
NZ (2) NZ332219A (es)
OA (1) OA10908A (es)
PL (1) PL188164B1 (es)
PT (1) PT904273E (es)
SI (1) SI0904273T1 (es)
SK (1) SK282674B6 (es)
TN (1) TNSN97073A1 (es)
TR (1) TR199802241T2 (es)
TW (1) TW427989B (es)
UA (1) UA47467C2 (es)
UY (1) UY24543A1 (es)
WO (1) WO1997042190A1 (es)
YU (1) YU49398B (es)
ZA (1) ZA973875B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
TW491847B (en) 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
EP0985414B1 (en) * 1998-05-26 2003-08-27 Pfizer Products Inc. Medicament for the treatment of glaucoma and ischemic retinopathy
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
AP2002002552A0 (en) 1999-12-23 2002-06-30 Pfizer Prod Inc Pharmaceutical compositions providing enhanced drug concentrations.
EP1286672B1 (en) * 2000-06-02 2006-10-25 Pfizer Products Inc. S-methyl-dihydro-ziprasidone for the treatment of ocular disorders.
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
US8703772B2 (en) 2001-09-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
UY27668A1 (es) * 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
WO2004050655A1 (en) * 2002-12-04 2004-06-17 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride
US7488729B2 (en) 2002-12-04 2009-02-10 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride salt and process for preparation thereof
EP1626722A1 (en) * 2003-05-16 2006-02-22 Pfizer Products Inc. Method for enhancing cognition using ziprasidone
EP1633360A1 (en) * 2003-05-16 2006-03-15 Pfizer Products Incorporated Treatment of psychotic and depressive disorders
BRPI0410419A (pt) * 2003-05-16 2006-05-30 Pfizer Prod Inc tratamento para a ansiedade com ziprasidona
EP1546146A1 (en) * 2003-06-03 2005-06-29 Teva Pharmaceutical Industries Limited POLYMORPHIC FORMS OF ZIPRASIDONE HCl AND PROCESSES FOR THEIR PREPARATION
MXPA06002455A (es) * 2003-09-02 2006-08-31 Pfizer Prod Inc Formas de dosificacion de liberacion sostenida de ziprasidona.
WO2005040160A2 (en) * 2003-10-24 2005-05-06 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
JP2007514001A (ja) * 2003-12-18 2007-05-31 テバ ファーマシューティカル インダストリーズ リミティド ジプラシドン塩基の多形形態ｂ２
CA2552126A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Ziprasidone formulations
PT1720867E (pt) * 2004-02-27 2010-01-28 Ranbaxy Lab Ltd Processo para a preparação de ziprasidona
US9044503B2 (en) * 2004-08-27 2015-06-02 University Of Kentucky Research Foundation Amyloid peptide inactivating enzyme to treat alzheimer's disease peripherally
ES2250001B1 (es) * 2004-09-29 2007-06-01 Medichem, S.A. Proceso para la purificacion de ziprasidona.
US7777037B2 (en) * 2004-10-27 2010-08-17 Dr. Reddy's Laboratories Limited Ziprasidone process
EA200701065A1 (ru) * 2004-11-16 2007-12-28 Элан Фарма Интернэшнл Лтд. Инъецируемые составы, содержащие нанодисперсный оланзапин
EP1863806A1 (en) * 2005-02-11 2007-12-12 Teva Pharmaceutical Industries Ltd Amorphous ziprasidone mesylate
EP1855651A4 (en) * 2005-03-03 2011-06-15 Elan Pharma Int Ltd NANOPARTICULAR COMPOSITIONS OF HETEROCYCLIC AMIDE DERIVATIVES
ITMI20050346A1 (it) 2005-03-07 2006-09-08 Dipharma Spa Forma solida di ziprasidone cloridrato
US20060270685A1 (en) * 2005-03-14 2006-11-30 Judith Aronhime Anhydrous ziprasidone mesylate and a process for its preparation
EP1858891A2 (en) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd. Crystalline forms of ziprasidone mesylate
CN101677568A (zh) * 2007-05-18 2010-03-24 赛多斯有限责任公司 齐拉西酮制剂
KR100948126B1 (ko) * 2007-12-10 2010-03-18 씨제이제일제당 (주) 결정형의 지프라시돈 술폰산염, 그 제조방법, 및 그것를포함하는 약제학적 조성물
CN102234273B (zh) * 2010-04-21 2015-08-05 上海医药工业研究院 甲磺酸齐拉西酮半水合物及其制备方法
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5359068A (en) * 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one

Also Published As

Publication number Publication date
AR007003A1 (es) 1999-10-13
WO1997042190A1 (en) 1997-11-13
JP3102896B2 (ja) 2000-10-23
YU17397A (sh) 2000-10-30
UA47467C2 (uk) 2002-07-15
KR20000010822A (ko) 2000-02-25
YU49398B (sh) 2005-11-28
HRP970235B1 (en) 2002-08-31
CA2252895C (en) 2002-08-20
KR100333214B1 (ko) 2002-06-20
HUP9902808A2 (hu) 2000-03-28
AU1936897A (en) 1997-11-26
EP0904273B1 (en) 2003-04-09
BG63601B1 (bg) 2002-06-28
NO985193D0 (no) 1998-11-06
IS2301B (is) 2007-10-15
NZ508303A (en) 2001-07-27
HN1997000040A (es) 1997-06-05
JPH11509865A (ja) 1999-08-31
PL188164B1 (pl) 2004-12-31
UY24543A1 (es) 2000-09-29
CN1092658C (zh) 2002-10-16
ES2192264T3 (es) 2003-10-01
IL126590A0 (en) 1999-08-17
SI0904273T1 (en) 2003-08-31
US6110918A (en) 2000-08-29
EA199800909A1 (ru) 1999-04-29
CA2252895A1 (en) 1997-11-13
ME00901B (me) 2005-11-28
PT904273E (pt) 2003-06-30
AP9700978A0 (en) 1997-07-31
HRP970235A2 (en) 1998-06-30
NO312513B1 (no) 2002-05-21
HK1017893A1 (en) 1999-12-03
AP838A (en) 2000-05-03
DZ2221A1 (fr) 2002-12-03
AU730856B2 (en) 2001-03-15
AU730856C (en) 2001-11-15
EA001180B1 (ru) 2000-10-30
ZA973875B (en) 1998-11-06
GT199700042A (es) 1998-10-02
ID17504A (id) 1998-01-08
SK282674B6 (sk) 2002-11-06
DE69720719T2 (de) 2003-11-06
BR9708932A (pt) 1999-08-03
CZ289216B6 (cs) 2001-12-12
DK0904273T3 (da) 2003-07-07
EG24401A (en) 2009-04-29
MA26427A1 (fr) 2004-12-20
OA10908A (en) 2001-10-26
PL329880A1 (en) 1999-04-12
CO4940465A1 (es) 2000-07-24
ATE236902T1 (de) 2003-04-15
TNSN97073A1 (fr) 2005-03-15
TW427989B (en) 2001-04-01
EP0904273A1 (en) 1999-03-31
CZ349498A3 (cs) 1999-09-15
TR199802241T2 (es) 1999-02-22
IS4878A (is) 1998-10-23
NO985193L (no) 1998-11-06
BG102893A (en) 1999-09-30
NZ332219A (en) 2005-02-25
SK150598A3 (en) 2000-03-13
MY128051A (en) 2007-01-31
HUP9902808A3 (en) 2000-04-28
HU229057B1 (en) 2013-07-29
CN1216990A (zh) 1999-05-19
DE69720719D1 (de) 2003-05-15

Similar Documents

Publication Publication Date Title
AP838A (en) Mesylate trihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-y1)-1-piperaziny1)-ethy1) -6-chloro-1,3-dihydro-2h-indol-2-one.
US6245765B1 (en) Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one (=ziprasidone), its preparation and its use as dopamine D2 antagonist
NZ508304A (en) Mesylate dihydrate salt of 5-(2-(4-(1,2 benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one ( ziprasidone) useful as dopamine D2 antagonist
MXPA98009242A (es) Sal mesilato trihidrato de 5-(-2-(4-(1,2-benzoisotiazol-3-il)-1-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired